Stephane Bancel, the CEO of Moderna, led a $47m Series D funding round in L-Nutra, a nutri-technology company, spearheading longevity science nutrition programs, with participation from Brentwood Associates. "We are proud to have the support of Mr. Stephane Bancel, one of the most successful biotech leaders of our time, who recently enhanced human longevity with Moderna's COVID vaccine. His personal investment in our company reinforces trust in our cutting-edge science and continued support of our global mission to increase longevity and healthspan across the glob. With Mr. Bancel's financial support, we can continue to expand ProLon across global markets. We will also be able to increase access to our first diabetes remission program, allowing patients to significantly reduce their reliance on medication in many casese," Joseph Antoun, L-Nutra CEO.